Imunon (NASDAQ:IMNN) Trading Down 2.3%

Shares of Imunon, Inc. (NASDAQ:IMNN) fell 2.3% during mid-day trading on Wednesday . The stock traded as low as $1.28 and last traded at $1.30. 32,389 shares were traded during mid-day trading, a decline of 83% from the average session volume of 186,613 shares. The stock had previously closed at $1.33.

Analysts Set New Price Targets

Separately, HC Wainwright boosted their price target on shares of Imunon from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, April 1st.

Imunon Trading Down 2.3 %

The stock has a market capitalization of $12.22 million, a price-to-earnings ratio of -0.60 and a beta of 2.03. The stock’s 50 day moving average is $1.09 and its two-hundred day moving average is $0.90.

Imunon (NASDAQ:IMNN) last announced its earnings results on Thursday, March 28th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.07. On average, research analysts anticipate that Imunon, Inc. will post -2.27 earnings per share for the current year.

About Imunon

Imunon, Inc, a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.